<DOC>
	<DOCNO>NCT01659086</DOCNO>
	<brief_summary>The purpose study evaluate safety , reactogenicity , immunogenicity different formulation two-dose primary series booster vaccination monovalent Influenza H9N2 vaccine manufacture Quebec , Canada without adjuvant , adult 18 64 year age .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity GlaxoSmithKline ( GSK ) Biologicals ' Influenza Vaccines GSK2654911A GSK2654909A Administered Adults 18 64 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female adult 18 64 year age ( inclusive ) time first study vaccination . Written inform consent obtain subject . Subjects investigator believe comply requirement protocol . Healthy subject establish medical history physical examination . Body weight least 110 lb ( 49.9 kg ) . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device ( i.e. , commonuse phone serve multiple room apartment ) . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue practice adequate contraception 2 month booster dose administration . Presence evidence neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence evidence substance abuse . Diagnosed cancer , treatment cancer within three year . Persons history cancer diseasefree without treatment three year eligible . Persons history histologicallyconfirmed basal cell carcinoma skin successfully treat local excision except may enroll , histologic type skin cancer exclusionary . Women diseasefree three year treatment breast cancer receive longterm prophylaxis may enroll . Presence temperature ≥ 38.0ºC ( ≥100.4ºF ) , acute symptom great `` mild '' severity schedule date first vaccination . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection ( laboratory testing require ) . Receipt systemic glucocorticoid ( e.g. , prednisone ≥ 10 mg/day 14 consecutive day ) within 30 day prior first dose study vaccine , cytotoxic , immunosuppressive immunemodifying drug within 365 day study enrollment . Topical , intraarticularly inject , inhaled glucocorticoid , topical calcineurin inhibitor imiquimod allow . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination eligible . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder Guillain Barré Syndrome within 42 day receipt prior seasonal pandemic influenza vaccine . Administration inactive vaccine within 14 day live attenuated vaccine within 30 day first dose study vaccine/product . Planned administration vaccine study vaccine/product blood sample Day 42 visit . Previous administration H9 vaccine physicianconfirmed H9 disease . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Receipt immunoglobulins and/or blood product within 90 day study enrolment plan administration product study period . Any known suspected allergy constituent influenza vaccine component use manufacturing process study vaccine include history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin ( βhCG ) test result first vaccination . Lactating nursing woman . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Influenza</keyword>
	<keyword>H9N2</keyword>
	<keyword>Safety</keyword>
</DOC>